Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06219759

Reinnervation and Neuromuscular Transmission in ALS

The aim of this study is to describe the changes in the neuromuscular connection in patients with amyotrophic lateral sclerosis (ALS). The study consist of three substudies that have the following main hypothesis:

1. that ALS patients do not demonstrate equal capacity for muscle reinnervation and that reinnervation preserves muscle function and thereby slows down progression. 2. that blood concentrations of c-terminal agrin fragment (bCAF) reflect neuromuscular transmission deficiency and that blood concentration of neural cell adhesion molecule reflects degree of muscle denervation in patients. 3. that ALS patients with decrement when examined with repetitive nerve stimulation have more physical fatigue, slower progression, higher degree of reinnervation and higher bCAF compared to ALS patients without decrement.

There will be 3 inclusion groups.

1. patients referred for neurophysiological examination on suspicion of motor neuron disease. 2. healthy controls 3. disease control: patients with another motor neuron disease with slow progression.

All participants will be invited for at least 1 visit (baseline). If participants in group 1 eventually receive the diagnosis of ALS they will be invited for 2 additional visits 4 og 8 months after baseline visit, respectively.

Examinations will consist of:

* nerve conduction study * repetitive nerve stimulation (except for healthy controls) to examine impairment of the neuromuscular connection. * motor unit number estimation with MScanFit to estimate number and size of motor units. * ultrasound examination of muscles to measure size and condition of muscles. * questionnaires on fatigue and functional status. * blood sample for measurement of specialized analysis (c-terminal agrin fragment and neural cell adhesion molecule) and routine analysis (liver and kidney function as well as neurofilament light chain) * muscle strength assessment manually and by dynamometer to follow progression of muscle weakness * bioelectrical impedance measurement to follow the overall body composition.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Department of Neurology, Aarhus University Hospital

Aarhus, Central Jutland, 8200, Denmark

Location status: Recruiting

Location contact

Jesper H Storgaard, MD

CONTACT

[email protected]

004520231903

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Referred to clinical neurophysiological examination on suspicion of motor neuron disease or diagnosed with ALS according to Gold Coast criteria within the last 3 months.
  • Age ≥18 years old
  • Able and willing to provide informed consent

Exclusion criteria

  • Former central or peripheral nervous system disease
  • Diabetes
  • Electrophysiological signs of polyneuropathy at baseline visit
  • Pacemaker
  • Pregnancy

For disease controls the exclusion criteria are the same, but the inclusion criteria:

  • Diagnosed with disease with slow, progressive loss of motor neurons
  • Age ≥18 years old
  • Able and willing to provide informed consent

Treatment and study plan

observational study

Other

Observational study.

Primary outcomes

  1. Reinnervation

    Time frame: From baseline and 8 months

    Difference between fast and slow progressing patients in change in mean amplitude size of motor units as estimated by MScanFit motor unit number estimation.

  2. Blood biomarkers

    Time frame: Baseline

    Difference in blood concentration of c-terminal agrin fragment and neural cell adhesion molecule at baseline between ALS patients, healthy controls and ALS mimic disease patients.

  3. Fatigue and decrement

    Time frame: Baseline

    Difference in proportion of participants with decrement between ALS patients and ALS mimic disease patients as well as degree of fatigue among ALS patients with and without neuromuscular transmission deficiency.

Other outcomes

  1. Difference in mean amplitude size over time in patients.

    Time frame: Baseline, 4 months and 8 months.

    Mean amplitude size measured by MScanFit technique.

  2. Difference in motor unit number estimation over time in patients.

    Time frame: Baseline, 4 months and 8 months.

    Motor unit number estimation measured by MScanFit technique.

  3. Difference in mean amplitude size between patients and control groups

    Time frame: Baseline.

    Mean amplitude size measured by MScanFit technique.

  4. Muscle strength assessed with manual muscle strength testing

    Time frame: Baseline, 4 months and 8 months.

    Difference in measures from manual muscle strength testing.

  5. Difference in isometric ankle dorsiflexion strength measured on dynamometer.

    Time frame: Baseline, 4 months and 8 months.

    Measured on dynamometer.

  6. Difference in handgrip strength measured on dynamometer.

    Time frame: Baseline, 4 months and 8 months.

    Measured with handgrip dynamometer.

  7. Correlation between decrement at repetitive nerve stimulation and signs of reinnervation as measured by mean amplitude size.

    Time frame: Baseline, 4 months and 8 months.

    Decrement measured with repetitive nerve stimulation and mean amplitude size measured with MScanFit technique.

  8. Blood concentration of c-terminal agrin fragment and neural cell adhesion molecule.

    Time frame: Baseline, 4 months and 8 months.

    Difference in blood measurements of c-terminal agrin fragment, neural cell adhesion molecule, neurofilament light chain and routine kidney and liver markers.

  9. Difference in muscle thickness as measured by ultrasound examination of muscles

    Time frame: Baseline, 4 months and 8 months.

    Measured by ultrasound examination.

  10. Amyotrophic Lateral Sclerosis Functional Rating Scale - Revised scores

    Time frame: Baseline, 4 months and 8 months.

    Difference in scores from Amyotrophic Lateral Sclerosis Functional Rating Scale - Revised. Scale 0-48, with 48 being the best.

  11. Multidimensional Fatigue Inventory scores

    Time frame: Baseline, 4 months and 8 months.

    Difference in scores from Multidimensional Fatigue Inventory. Scale 4-20, with 20 indicating worst degree of fatigue.

  12. Fatigue Severity Scale scores

    Time frame: Baseline, 4 months and 8 months.

    Difference in scores from Fatigue Severity Scale. Scale 9-63, with 63 indicating worst degree of fatigue.

  13. Difference in free fatt mass as measured by bioelectrical impedance analysis.

    Time frame: Baseline, 4 months and 8 months.

    Measured by bioelectrical impedance analysis.

Study contacts

Contact information is provided by the study sponsor or research team.

Jesper Storgaard, MD

CONTACT

[email protected]

004520231903

Sponsors and collaborators

Lead sponsor

University of Aarhus

Other

Collaborators

  • Aarhus University Hospital

Registry information

Official study title

Reinnervation and Neuromuscular Transmission in Patients With Amyotrophic Lateral Sclerosis

Acronym: RANTAL

Important dates

Study start
2024
Primary completion
2026
Study completion
2026
First posted
Jan 23, 2024
Registry last updated
Aug 7, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.